Company: XAIR
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023243
Chunk: 84

Company: Beyond Air, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part II, Item 8
Chunk 84
---
 1.8 years.

For
the three months June 30, 2025, the weighted average fair value of options granted was $2.38 per share.

    17

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
4 STOCKHOLDERS’ EQUITY (continued)

The
following was utilized to calculate the fair value of options on the date of grant:

SCHEDULE OF FAIR VALUE OF OPTION  

    June 30, 2025  
    June 30, 2024 
  
    Risk-free interest rate 
     4.0 – 4.2% 
     4.3 – 4.5%
  
    Expected volatility (Beyond Air) 
     91.6 – 95.7% 
     83.5 – 83.8%
  
    Expected volatility (Beyond Cancer) 
     -% 
     -%
  
    Expected volatility (NeuroNos) 
     95.0% 
     -%
  
    Dividend yield 
     0% 
     0%
  
    Expected terms (in years) 
     6.25  
     6.25 

The
Company determined that the fair value per share of NeuroNos’ common stock to be $3.00 at the grant date during the three months
ended June 30, 2025 based on the valuation of common stock purchased by external investors during March 2025.

The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock units for the
three months ended June 30, 2025 and June 30, 2024:

 SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE 

    2025  
    2024 

    Three Months Ended 
  
    (in thousands) 
    June 30, 

    2025  
    2024 

    Research and development 
    $300  
    $629 
  
    General and administrative 
     1,277  
     2,750 
  
    Total stock-based compensation expense 
    $1,577  
    $3,379 

Warrants

A
summary of the Company’s outstanding warrants as of June 30, 2025 is as follows:

 SUM